Implications of hepatitis C viremia vs. antibody alone on transmission among male injecting drug users in three Afghan cities

International Journal of Infectious Diseases

Volumn 15, Issue 3, 2011, Pages

  Nasir, Abdul ^a   Todd, Catherine S ^b   Stanekzai, Mohammad R ^a   Bautista, Christian T ^c   Botros, Boulos A ^d   Scott, Paul T ^c   Kim, Jerome H ^c   Strathdee, Steffanie A ^e   Tjaden, Jeffrey ^d  

^a INTERNATIONAL RESCUE COMMITTEE   (Afghanistan)

^b Columbia University ^*  (United States)

^c US Military HIV Research Program   (United States)

^d US Naval Medical Research Unit No 3 Egypt   (Egypt)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Afghanistan; Harm reduction; HCV; HIV HCV co infection; Injecting drug user

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; AFGHANISTAN; ARTICLE; BLOODSTREAM INFECTION; DISEASE TRANSMISSION; DRUG USE; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PREVALENCE; QUESTIONNAIRE; RISK ASSESSMENT; VIRUS INFECTION; VIRUS TRANSMISSION;

ADULT; AFGHANISTAN; CROSS-SECTIONAL STUDIES; DISEASE TRANSMISSION, INFECTIOUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOBLOTTING; MALE; QUESTIONNAIRES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; VIREMIA;

EID: 79952101004     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.11.006     Document Type: Article

References (33)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
2. Maheshwari A., Ray S., Thuluvath P.J. Acute hepatitis C. Lancet 2008, 372:321-332.
3. Azim T., Chowdhury E.I., Reza M., Faruque M.O., Ahmed G., Khan R., et al. Prevalence of infections, HIV risk behaviors and factors associated with HIV infection among male injecting drug users attending a needle/syringe exchange program in Dhaka, Bangladesh. Subst Use Misuse 2008, 43:2124-2144.
4. Kageyama S., Agdamag D.M., Alesna E.T., Abellanosa-Tac-An I.P., Corpuz A.C., Telan E.F., et al. Tracking the entry routes of hepatitis C virus as a surrogate of HIV in an HIV-low prevalence country, the Philippines. J Med Virol 2009, 81:1157-1162.
5. Des Jarlais D.C., Arasteh K., Semaan S., Wood E. HIV among injecting drug users: current epidemiology, biologic markers, respondent-driven sampling, and supervised-injection facilities. Curr Opin HIV AIDS 2009, 4:308-313.
6. Zamani S., Ichikawa S., Nassirimanesh B., Vazirian M., Ichikawa K., Gouya M.M., et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007, 18:359-363.
7. Platt L., Vickerman P., Collumbien M., Hasan S., Lalji N., Mayhew S., et al. Prevalence of HIV, HCV and sexually transmitted infections among injecting drug users in Rawalpindi and Abbottabad, Pakistan: evidence for an emerging injection-related HIV epidemic. Sex Transm Infect 2009, 85(Suppl 2):ii17-22.
8. Mahanta J., Medhi G.K., Paranjape R.S., Roy N., Kohli A., Akoijam B.S., et al. Injecting and sexual risk behaviours, sexually transmitted infections and HIV prevalence in injecting drug users in three states in India. AIDS 2008, 22(Suppl 5):S59-68. IBBA study team.
9. Kuo I., ul-Hasan S., Galai N., Thomas D.L., Zafar T., Ahmed M.A., et al. High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J 2006, 3:26.
10. Todd C.S., Abed A.M., Strathdee S.A., Scott P.T., Botros B.A., Safi N., et al. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis 2007, 13:1327-1331.
11. Nasir A., Todd C.S., Stanekzai M.R., Bautista C.T., Strathdee S.A., Scott P.T., et al. Prevalence of HIV, viral hepatitis, syphilis and risk behaviors among injection drug users in Hirat, Afghanistan. Abstract MOPE-0280. Programs and Abstracts of the 17th International AIDS Conference, Vol. 1 (Mexico City) 2008, 118.
12. United Nations Office on Drugs and Crime (UNODC). Afghanistan drug use survey 2005. Kabul, Afghanistan: UNODC; 2006.
13. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., et al. Protection against persistence of hepatitis C. Lancet 2002, 359:1478-1483.
14. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., Tyndall M.W. Hepatitis C virus reinfection in injection drug users. Hepatology 2006, 44:1139-1145.
15. Todd C.S., Nasir A., Stanekzai M.R., Rasuli M.Z., Fiekert K., Orr M.G., et al. Hepatitis C and HIV incidence among injecting drug users in Kabul, Afghanistan. Abstract MOPDC101. XVIII International AIDS Conference 2010.
16. Todd C.S., Nasir A., Stanekzai M.R., Bautista C.T., Botros B.A., Scott P.T., et al. HIV, hepatitis B, and hepatitis C prevalence and associated risk behaviors among female sex workers in three Afghan cities. AIDS 2010, 24(Suppl 2):S69-75.
17. Standard Diagnostics. SD Bioline HCV factsheet. Available at: (accessed November 30, 2010). http://standardia.com/html_e/mn03/mn03_01_00.asp?intId=13.
18. Ray S.C., Arthur R.R., Carella A., Bukh J., Thomas D.L. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000, 182:698-707.
19. Beld M., Penning M., van Putten M., van den Hoek A., Damen M., Klein M.R., et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999, 94:1183-1191.
20. Thomas D.L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfein R., et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995, 74:212-220.
21. Hall C.S., Charlebois E.D., Hahn J.A., Moss A.R., Bangsberg D.R. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004, 19:357-365.
22. Hallinan R., Byrne A., Amin J., Dore G.J. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005, 20:1082-1086.
23. Fishbein D.A., Lo Y., Netski D., Thomas D.L., Klein R.S. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. J Acquir Immune Defic Syndr 2006, 41:471-476.
24. Thomas D.L., Rich J.D., Schuman P. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis 2001, 183:973-976.
25. Operskalski E.A., Mack W.J., Strickler H.D., French A.L., Augenbraun M., Tien P.C., et al. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol 2008, 41:255-263.
26. Zhang M., Rosenberg P.S., Brown D.L., Preiss L., Konkle B.A., Eyster M.E., et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 2006, 107:892-897. Second Multicenter Hemophilia Cohort Study.
27. Zhang C., Yang R., Xia X., Qin S., Dai J., Zhang Z., et al. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J Acquir Immune Defic Syndr 2002, 29:191-196.
28. Solomon S.S., Srikrishnan A.K., Mehta S.H., Vasudevan C.K., Murugavel K.G., Thamburaj E., et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr 2008, 49:327-332.
29. Dolan K., Kite B., Black E., Aceijas C., Stimson G.V. HIV in prison in low-income and middle-income countries. Lancet Infect Dis 2007, 7:32-41. Reference Group on HIV/AIDS Prevention and Care among Injecting Drug Users in Developing and Transitional Countries.
30. Sarang A., Rhodes T., Platt L., Kirzhanova V., Shelkovnikova O., Volnov V., et al. Drug injecting and syringe use in the HIV risk environment of Russian penitentiary institutions: qualitative study. Addiction 2006, 101:1787-1796.
31. Micallef J.M., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007, 14:413-418.
32. Aitken C.K., Lewis J., Tracy S.L., Spelman T., Bowden D.S., Bharadwajet M., et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008, 48:1746-1752.
33. Lehmann M., Meyer M.F., Monazahian M., Tillmann H.L., Manns M.P., Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 2004, 73:387-391.